Drug removal of gastric acid: a novel treatment of metabolic acidosis

Affiliations

¹ Medical and Research Services Veterans Administration Greater Los Angeles (VHAGLA) Healthcare System, and Division of Nephrology VHAGLA Healthcare System, UCLA Membrane Biology Laboratory, and UCLA David Geffen School of Medicine Sciences Los Angeles, Los Angeles, CA 90073, USA. Electronic address: jkraut@ucla.edu.
² Veterans Affairs Salt Lake City Healthcare System and Department of Internal Medicine, University of Utah Health, Salt Lake City, UT, USA.

Comment

Jeffrey A Kraut et al. Lancet. 2019.

. 2019 Aug 3;394(10196):363-364.

doi: 10.1016/S0140-6736(19)31473-4. Epub 2019 Jun 24.

¹ Medical and Research Services Veterans Administration Greater Los Angeles (VHAGLA) Healthcare System, and Division of Nephrology VHAGLA Healthcare System, UCLA Membrane Biology Laboratory, and UCLA David Geffen School of Medicine Sciences Los Angeles, Los Angeles, CA 90073, USA. Electronic address: jkraut@ucla.edu.
² Veterans Affairs Salt Lake City Healthcare System and Department of Internal Medicine, University of Utah Health, Salt Lake City, UT, USA.

No abstract available

Comment on

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.
Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, Klaerner G, Bushinsky DA. Wesson DE, et al. Lancet. 2019 Aug 3;394(10196):396-406. doi: 10.1016/S0140-6736(19)31388-1. Epub 2019 Jun 24. Lancet. 2019. PMID: 31248662 Clinical Trial.